Managing cardiovascular risk in type 2 diabetes requires strict adherence to evidence-based protocols. The TEMD-2 study evaluated LDL cholesterol targets in diabetes across 36 cities in Turkey. Researchers analyzed 4,956 adults to assess guideline implementation in clinical practice. Surprisingly, fewer than one in ten patients achieved their required lipid goals.

Challenges in Reaching LDL Cholesterol Targets in Diabetes

The study highlighted a massive gap between guidelines and real-world outcomes. Although 99.5% of the participants required statin therapy, only 37.1% were using it. Furthermore, overall target attainment was a mere 8.3%. Patients at very high cardiovascular risk fared the worst, with only 5.8% reaching goals. Moreover, statin users showed better results in moderate-risk categories compared to high-risk ones.

Several clinical factors influenced these outcomes significantly. For instance, statin therapy served as the strongest positive predictor for success. On the other hand, smoking, neuropathy, and higher HbA1c levels decreased the likelihood of success. Female patients and older individuals also faced greater difficulties in reaching targets. Therefore, personalized strategies are necessary to address these specific patient barriers.

In addition to patient factors, therapeutic inertia played a critical role. Researchers identified inertia in 87.2% of patients who were above target. This means that clinicians failed to intensify treatment despite high cholesterol levels. Consequently, this shortfall increases the future burden of cardiovascular morbidity and premature mortality. Addressing this clinical delay is essential for improving long-term diabetes outcomes.

Frequently Asked Questions

What were the achievement rates for LDL-C targets in the study?

Overall, only 8.3% of the patients achieved their LDL-C targets. Achievement was lowest in the very-high-risk group at only 5.8%.

What is therapeutic inertia in diabetes management?

Therapeutic inertia occurs when healthcare providers do not intensify lipid-lowering therapy despite patients having LDL-C levels above the recommended targets. This study found inertia in 87.2% of cases.

Which factors hindered reaching lipid goals?

The study found that smoking, female sex, older age, and higher HbA1c were associated with a lower likelihood of success. Complications like neuropathy and nephropathy also reduced the chances of achieving targets.

Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Caklili OT et al. Suboptimal LDL-Cholesterol Control Under the 2019 ESC/EAS Dyslipidemia Guidelines: Results From the Nationwide TEMD-2 Study in Type 2 Diabetes. Diabetes Obes Metab. 2026 May 06. doi: 10.1111/dom.70806. PMID: 42092235.

2. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.

3. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S179-S218.